Supplemental Figure 1 from IL10 Release upon PD-1 Blockade Sustains Immunosuppression in Ovarian Cancer
Purushottam Lamichhane(Mayo Clinic), Keith L. Knutson(WinnMed), Ellen L. Goode(Mayo Clinic in Arizona), Lavakumar Karyampudi(Mayo Clinic), Joshua Daum(Jacksonville College), Deborah Bahr(Mayo Clinic in Florida), Kimberly R. Kalli(Mayo Clinic), James Krempski(University of North Carolina at Chapel Hill), Barath Shreeder(Mayo Clinic), Martin J. Cannon(University of Arkansas for Medical Sciences), Matthew S. Block(Mayo Clinic in Arizona)
Cited by 0
Related Papers
Associations of Breast Cancer Risk Factors With Tumor Subtypes: A Pooled Analysis From the Breast Cancer Association Consortium Studies
|JNCI Journal of the National Cancer Institute|2010|716
Germline Mutations in the BRIP1, BARD1, PALB2, and NBN Genes in Women With Ovarian Cancer
|JNCI Journal of the National Cancer Institute|2015|441
Hormone-receptor expression and ovarian cancer survival: an Ovarian Tumor Tissue Analysis consortium study
|The Lancet Oncology|2013|434